Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RPRX's Cash to Debt is ranked higher than
78% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. RPRX: No Debt )
RPRX' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: No Debt

Equity to Asset 0.94
RPRX's Equity to Asset is ranked higher than
97% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. RPRX: 0.94 )
RPRX' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.99
Current: 0.94

0.09
0.99
Interest Coverage No Debt
RPRX's Interest Coverage is ranked higher than
81% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RPRX: No Debt )
RPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 68.66
M-Score: -1.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -308011.11
RPRX's Operating margin (%) is ranked lower than
53% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. RPRX: -308011.11 )
RPRX' s 10-Year Operating margin (%) Range
Min: -624550   Max: -101.1
Current: -308011.11

-624550
-101.1
Net-margin (%) -308011.11
RPRX's Net-margin (%) is ranked lower than
53% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. RPRX: -308011.11 )
RPRX' s 10-Year Net-margin (%) Range
Min: -624550   Max: -35.93
Current: -308011.11

-624550
-35.93
ROE (%) -36.75
RPRX's ROE (%) is ranked higher than
66% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. RPRX: -36.75 )
RPRX' s 10-Year ROE (%) Range
Min: -4845.91   Max: -2.74
Current: -36.75

-4845.91
-2.74
ROA (%) -35.10
RPRX's ROA (%) is ranked higher than
65% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. RPRX: -35.10 )
RPRX' s 10-Year ROA (%) Range
Min: -920.07   Max: -2.27
Current: -35.1

-920.07
-2.27
ROC (Joel Greenblatt) (%) -36961.33
RPRX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. RPRX: -36961.33 )
RPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -226950   Max: -180.12
Current: -36961.33

-226950
-180.12
Revenue Growth (%) -100.00
RPRX's Revenue Growth (%) is ranked higher than
52% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. RPRX: -100.00 )
RPRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 183.2
Current: -100

0
183.2
EBITDA Growth (%) 31.50
RPRX's EBITDA Growth (%) is ranked higher than
96% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. RPRX: 31.50 )
RPRX' s 10-Year EBITDA Growth (%) Range
Min: -51.7   Max: 68.7
Current: 31.5

-51.7
68.7
EPS Growth (%) 31.10
RPRX's EPS Growth (%) is ranked higher than
94% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. RPRX: 31.10 )
RPRX' s 10-Year EPS Growth (%) Range
Min: -59   Max: 112.8
Current: 31.1

-59
112.8
» RPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

RPRX Guru Trades in Q2 2013

Steven Cohen 1,400 sh (-99.89%)
» More
Q3 2013

RPRX Guru Trades in Q3 2013

Steven Cohen 2,603 sh (+85.93%)
» More
Q4 2013

RPRX Guru Trades in Q4 2013

Steven Cohen Sold Out
» More
Q2 2014

RPRX Guru Trades in Q2 2014

Steven Cohen 100,268 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with RPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.43
RPRX's P/B is ranked higher than
59% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. RPRX: 8.43 )
RPRX' s 10-Year P/B Range
Min: 0.52   Max: 80.71
Current: 8.43

0.52
80.71
EV-to-EBIT -14.42
RPRX's EV-to-EBIT is ranked higher than
55% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RPRX: -14.42 )
RPRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -14.42

Current Ratio 14.94
RPRX's Current Ratio is ranked higher than
94% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. RPRX: 14.94 )
RPRX' s 10-Year Current Ratio Range
Min: 0.23   Max: 66.45
Current: 14.94

0.23
66.45
Quick Ratio 14.94
RPRX's Quick Ratio is ranked higher than
94% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. RPRX: 14.94 )
RPRX' s 10-Year Quick Ratio Range
Min: 0.23   Max: 66.45
Current: 14.94

0.23
66.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.94
RPRX's Price/Net Cash is ranked higher than
89% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. RPRX: 8.94 )
RPRX' s 10-Year Price/Net Cash Range
Min: 0.45   Max: 84.15
Current: 8.94

0.45
84.15
Price/Net Current Asset Value 8.94
RPRX's Price/Net Current Asset Value is ranked higher than
88% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. RPRX: 8.94 )
RPRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 533.33
Current: 8.94

0.44
533.33
Price/Tangible Book 8.88
RPRX's Price/Tangible Book is ranked higher than
76% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. RPRX: 8.88 )
RPRX' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 100.57
Current: 8.88

0.42
100.57
Earnings Yield (Greenblatt) 867.10
RPRX's Earnings Yield (Greenblatt) is ranked higher than
97% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RPRX: 867.10 )
RPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 1509.7
Current: 867.1

0
1509.7
Forward Rate of Return (Yacktman) -28.21
RPRX's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. RPRX: -28.21 )
RPRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5976.9   Max: -5496
Current: -28.21

-5976.9
-5496

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ZONN.Germany
Repros Therapeutics Inc. was organized on August 20, 1987. It is a development stage biopharmaceutical Company focusing on the development of oral small molecule drugs for major unmet medical needs. The Company's current product pipeline consists of: Proellex for female reproductive health and Androxal for male reproductive health. The company's drug, Proellex, is a selective blocker of the progesterone receptor. It is developing Proellex for three indications: anemia associated with uterine fibroids, chronic treatment of symptoms associated with uterine fibroids and chronic treatment of symptoms associated with endometriosis. The company's second product candidate, Androxal is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. The company was previously developing Androxal in the United States to treat testosterone deficiency due to secondary hypogonadism by restoring normal testosterone production in males with functional testes and diminished pituitary function, a common condition in the aging male. The company is also continuing limited out-licensing efforts for its phentolamine-based product candidates, including VASOMAX, which had previously been approved for marketing in several countries in Latin America for the treatment of male erectile dysfunction under the brand name, Z-Max. VASOMAX is currently on partial clinical hold in the U.S. The Company would continue to explore corporate partnering opportunities for assistance in the clinical development funding and commercialization of its products.
» More Articles for RPRX

Headlines

Articles On GuruFocus.com
comment on RPRX Mar 06 2013 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
promotes testosteron Jun 22 2011 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 


More From Other Websites
Repros Reports Encouraging Late-Stage Data on Androxal Aug 28 2014
Williams-Sonoma Stumbles After Yesterday's Surge Aug 28 2014
Why Repros Therapeutics (RPRX) Stock Is Surging Today Aug 28 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Aug 28 2014
Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various... Aug 27 2014
Repros Therapeutics (RPRX) Shows Strength: Stock Rises 5% Aug 22 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Aug 20 2014
REPROS THERAPEUTICS INC. Financials Aug 19 2014
Repros Therapeutics Q2 Loss a Penny Wider than Expected Aug 12 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 11 2014
Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results Aug 11 2014
Repros Gets Additional FDA Guidance for Androxal Jul 17 2014
FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus... Jul 16 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Jul 16 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 20 2014
Repros Therapeutics reaches enrollment goal in second Androxal study May 13 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure May 13 2014
Repros' Q1 Loss In Line with Expectations May 13 2014
Repros Therapeutics reports Q1 EPS (37c), consensus (35c) May 12 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK